当前位置:首页 - 行情中心 - 泽璟制药-U(688266) - 财务分析 - 现金流量表

泽璟制药-U

(688266)

  

流通市值:221.24亿  总市值:221.24亿
流通股本:2.65亿   总股本:2.65亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,672,860,476.621,265,861,458.68942,973,341.74893,841,042.09
  收到其他与经营活动有关的现金230,248,333.79225,668,877.49201,757,747.59161,640,556.03
  经营活动现金流入小计1,903,108,810.411,491,530,336.171,144,731,089.331,055,481,598.12
  购买商品、接受劳务支付的现金57,404,048.5331,477,314.0411,601,930.2942,077,111.98
  支付给职工以及为职工支付的现金300,473,383.28209,890,271.94117,092,176.67343,267,920.11
  支付的各项税费64,285,248.7743,115,278.4517,789,141.9780,563,439.98
  支付其他与经营活动有关的现金647,763,448.14398,533,558.62160,833,344.28618,355,112.29
  经营活动现金流出小计1,069,926,128.72683,016,423.05307,316,593.211,084,263,584.36
  经营活动产生的现金流量净额833,182,681.69808,513,913.12837,414,496.12-28,781,986.24
二、投资活动产生的现金流量:
  收回投资收到的现金2,726,268,679.681,901,152,926.26396,585,777.77116,123,500
  取得投资收益收到的现金119,762,060.74115,156,212.6531,652,958.349,708,791.34
  投资活动现金流入小计2,846,030,740.422,016,309,138.91428,238,736.11125,832,291.34
  购建固定资产、无形资产和其他长期资产支付的现金72,557,761.5949,416,816.333,799,619.54181,466,703.44
  投资支付的现金2,609,454,330.321,554,454,330.32999,454,330.32-
  投资活动现金流出小计2,682,012,091.911,603,871,146.621,033,253,949.86181,466,703.44
  投资活动产生的现金流量净额164,018,648.51412,437,992.29-605,015,213.75-55,634,412.1
三、筹资活动产生的现金流量:
  取得借款收到的现金56,000,00056,000,00056,000,0001,126,882,468.69
  筹资活动现金流入小计56,000,00056,000,00056,000,0001,126,882,468.69
  偿还债务支付的现金622,399,999.99370,200,000.03201,900,0001,009,900,000.01
  分配股利、利润或偿付利息支付的现金14,649,160.4110,942,041.825,794,834.326,094,317.79
  支付其他与筹资活动有关的现金25,090,324.2312,487,913.846,286,829.4498,389,163.06
  筹资活动现金流出小计662,139,484.63393,629,955.69213,981,663.741,134,383,480.86
  筹资活动产生的现金流量净额-606,139,484.63-337,629,955.69-157,981,663.74-7,501,012.17
四、汇率变动对现金及现金等价物的影响-7,111,613.37-5,348,578.27-4,503,785.11-690,409.18
五、现金及现金等价物净增加额383,950,232.2877,973,371.4569,913,833.52-92,607,819.69
  加:期初现金及现金等价物余额124,657,673.39124,657,673.39124,657,673.39217,265,493.08
  期末现金及现金等价物余额508,607,905.591,002,631,044.84194,571,506.91124,657,673.39
补充资料:
  净利润-640,011,104.13--165,126,809.51
  资产减值准备-5,320,810.83-3,358,105.87
  固定资产和投资性房地产折旧-10,407,581.7-23,670,592.77
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-10,407,581.7-23,670,592.77
  无形资产摊销-5,958,398.69-18,628,973.79
  长期待摊费用摊销-2,100,944.51-5,628,883.62
  处置固定资产、无形资产和其他长期资产的损失-19,991.64--810.44
  固定资产报废损失-1,999.23--
  公允价值变动损失--1,553,465.55--841,343.86
  财务费用-3,471,836.86--29,626,727.88
  投资损失--1,002,696.24--358,908.26
  递延所得税--1,610,428.25--3,996,929.58
    递延所得税负债增加--1,610,428.25--3,996,929.58
  存货的减少--24,926,294.72-9,594,088.46
  经营性应收项目的减少--62,042,396.89--24,395,644.32
  经营性应付项目的增加-225,637,556.92-123,550,059.88
  其他---3,339,332.01
  不涉及现金收支的投资和筹资活动金额其他项目---0
  现金的期末余额-1,002,631,044.84-124,657,673.39
  减:现金的期初余额-124,657,673.39-217,265,493.08
  现金及现金等价物的净增加额-877,973,371.45--92,607,819.69
公告日期2026-10-312026-08-012026-04-292026-03-28
审计意见(境内)标准无保留意见
TOP↑